A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

Trial Profile

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Ipilimumab (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 21 Nov 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 29 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top